Table 3 Intensive care and surgical management during the study period
Management/Treatment | All CDH cases | Survivors | Non-survivors |
|---|---|---|---|
Mechanical ventilation | 92 (97%) | 71 (96%) | 21 (100%) |
HFO | 75 (79%) | 56 (76%) | 19 (90%) |
iNO | 36 (38%) | 18 (24%) | 18 (86%) |
Magnesium, iv | 14 (15%) | 6 (8%) | 8 (38%) |
Sildenafil, ga | 13 (14%) | 6 (8%) | 7 (33%) |
Surfactant | 13 (14%) | 5 (7%) | 8 (38%) |
Vasoactive drugs | 60 (63%) | 39 (53%) | 21 (100%) |
Nor-epinephrine | 15 (16%) | 6 (8%) | 9 (43%) |
Dopamine | 51 (54%) | 34 (46%) | 17 (81%) |
Dobutamine | 16 (17%) | 9 (12%) | 7 (33%) |
Milrinone | 14 (15%) | 5 (7%) | 9 (43%) |
Epinephrine | 12 (13%) | 1 (1%) | 11 (52%) |
Sedatives | 80 (84%) | 59 (80%) | 21 (100%) |
Fentanyl | 77 (81%) | 57 (77%) | 20 (95%) |
Midazolam | 54 (57%) | 39 (53%) | 18 (86%) |
Methadone | 11 (12%) | 11 (15%) | 0 (0%) |
Phenobarbital | 43 (45%) | 37 (50%) | 6 (29%) |
Clonidine | 10 (11%) | 9 (12%) | 1 (5%) |
Operation | 84 (88%) | 74 (100%) | 10 (48%) |
Patch repair (operation) | 17 (20%) | 12 (16%) | 5 (50%) |
Recurrent hernia (operation) | 8 (8%) | 7 (10%) | 1 (1%) |